- ISIN
- US14888U1016
- CUSIP
- 14888U101
- Delisting Date
- Jul 16, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 8, 2006
Highlights
- Market Cap
- $3.85B
- Enterprise Value
- $3.10B
- EPS (TTM)
- $1.74
- PE Ratio
- 18.08
- PEG Ratio
- 0.32
- Total Revenue (TTM)
- $596.96M
- Gross Profit (TTM)
- $378.23M
- EBITDA (TTM)
- $313.50M
- Year Range
- $19.05 - $32.56
- Target Price
- $32.00
- ROA (TTM)
- 19.29%
- ROE (TTM)
- 21.85%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CPRX Performance Chart
Loading charts...
Compare this symbol against anything
Returns By Period
Catalyst Pharmaceuticals, Inc. (CPRX) has returned 34.92% so far this year and 49.10% over the past 12 months. Looking at the last ten years, CPRX has achieved an annualized return of 44.91%, outperforming the S&P 500 Index benchmark, which averaged 13.26% per year.
Catalyst Pharmaceuticals, Inc.
- 1D
- 0.00%
- 1M
- 0.13%
- 6M
- 29.59%
- YTD
- 34.92%
- 1Y
- 49.10%
- 3Y*
- 32.72%
- 5Y*
- 41.46%
- 10Y*
- 44.91%
- ALL TIME*
- 8.79%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CPRX Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.11% | -5.02% | 7.28% | 13.61% | 11.02% | 0.64% | 0.19% | 34.92% | |||||
| 2025 | 8.10% | 1.46% | 5.94% | 0.16% | 2.76% | -13.06% | -1.71% | -3.47% | -4.32% | 7.97% | 10.06% | -0.30% | 11.84% |
| 2024 | -14.34% | 11.32% | -0.56% | -5.58% | 7.44% | -4.21% | 11.30% | 17.46% | -1.83% | 9.66% | 1.24% | -5.44% | 24.15% |
| 2023 | -16.72% | -1.48% | 8.65% | -3.98% | -27.45% | 16.36% | 2.90% | 1.52% | -16.74% | 6.16% | 16.28% | 16.49% | -9.62% |
| 2022 | -14.92% | 35.42% | 6.28% | -8.08% | -5.51% | -2.64% | 46.08% | 32.23% | -5.24% | 8.11% | 20.91% | 10.91% | 174.74% |
| 2021 | 8.98% | 6.87% | 18.51% | -0.65% | 20.74% | 3.98% | 1.57% | -5.65% | -3.81% | 11.32% | 18.64% | -3.29% | 102.69% |
Benchmark Metrics
Catalyst Pharmaceuticals, Inc. has an annualized alpha of 50.97%, beta of 0.82, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 08, 2006.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (80.30%) than losses (79.80%) - typical of diversified or defensive assets.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 50.97%
- Beta
- 0.82
- R²
- 0.03
- Upside Capture
- 80.30%
- Downside Capture
- 79.80%
Return for Risk
Risk / Return Rank
CPRX ranks 86 for risk / return — above 86% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CPRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.12 | ||
| Sortino ratioReturn per unit of downside risk | +0.16 | ||
| Omega ratioGain probability vs. loss probability | 1.31 | 1.25 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 3.52 | 2.00 | +1.51 |
| Martin ratioReturn relative to average drawdown | 9.42 | 8.49 | +0.93 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Catalyst Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Catalyst Pharmaceuticals, Inc. was 94.25%, occurring on Nov 12, 2012. Recovery took 1717 trading sessions.
The current Catalyst Pharmaceuticals, Inc. drawdown is 0.03%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-94.25%Nov 2012 | 5y 9mo | 6y 10mo | 12y 7moFeb 2007 - Sep 2019 | — |
-64.87%Mar 2020 | 6mo 6d | 1y 8mo | 2y 2moSep 2019 - Nov 2021 | COVID crash2020 |
-45.37%May 2023 | 4mo 9d | 1y 3mo | 1y 8moJan 2023 - Sep 2024 | — |
-38.21%Jan 2007 | 2mo 15d | 7d | 2mo 22dNov 2006 - Jan 2007 | — |
-28.72%Jan 2022 | 2mo 10d | 15d | 2mo 25dNov 2021 - Feb 2022 | Bear market2022 |
Drawdown Indicators
| CPRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.25% | -56.78% | -37.47% |
Max Drawdown (1Y)Largest decline over 1 year | -13.91% | -9.10% | -4.81% |
Max Drawdown (3Y)Largest decline over 3 years | -27.29% | -18.90% | -8.39% |
Max Drawdown (5Y)Largest decline over 5 years | -45.37% | -25.43% | -19.94% |
Max Drawdown (10Y)Largest decline over 10 years | -64.87% | -33.92% | -30.95% |
Current DrawdownCurrent decline from peak | -0.03% | -1.58% | +1.55% |
Average DrawdownAverage peak-to-trough decline | -51.73% | -10.70% | -41.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.18% | 2.14% | +3.04% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Catalyst Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Catalyst Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CPRX, comparing it with other companies in the Biotechnology industry. Currently, CPRX has a P/E ratio of 18.1. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CPRX compared to other companies in the Biotechnology industry. CPRX currently has a PEG ratio of 0.3. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CPRX relative to other companies in the Biotechnology industry. Currently, CPRX has a P/S ratio of 6.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CPRX in comparison with other companies in the Biotechnology industry. Currently, CPRX has a P/B value of 3.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CPRX
Add Catalyst Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CPRX